Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss

Drug Targets GLP-1 And Glucagon Receptors

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Survodutide provides another obesity treatment option, albeit with gastrointestinal side effects that will need to be managed with slow titration to maintenance dosing, which will be tested in Phase III.

Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock

Data for the Boehringer Ingelheim GmbH/Zealand Pharma A/S drug candidate survodutide (BI 456906) presented at the American Diabetes Association (ADA) annual meeting in San Diego showed that at the highest dose of 4.8mg once weekly, patients who were overweight or obese and who remained on treatment for the full 46 weeks of the companies’ Phase II clinical trial achieved 18.7% weight loss, potentially offering an additional option for doctors prescribing GLP-1-targeting medicines.

Unlike Novo Nordisk A/S’s US Food and Drug Administration-approved GLP-1 agonist Wegovy (semaglutide) for obesity and Eli Lilly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D